PAN-TB Collaboration Announces Novel TB Drug Regimens Trial


The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-profit, philanthropic, and private sector partners for a common mission to develop novel TB medicines that are better-tolerated, shorter in duration, and simpler to use than existing options. The collaboration includes members such as Evotec, GSK, Janssen, Otsuka, TB Alliance, the Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Bill & Melinda Gates Foundation.

The Phase 2 study announced by Gates MRI last week will evaluate 2 novel drug regimens comprising of 5 anti-TB chemical entities, some of which are currently approved for treatment of TB and new chemical entities to the treatment of TB. The anti-TB agents are:

The two drug regimens under investigation in this clinical trial are:

  • DBOS – Delamanid, Bedaquiline, OPC-167832, and Sutezolid
  • PBOS – Pretomanid, Bedaquiline, OPC-167832, and Sutezolid

The 5 drugs and drug candidates are owned by 4 of the PAN-TB consortium’s members: Janssen Pharmaceutica (Bedaquiline), Otsuka Pharmaceutical (Delamanid & OPC-157832), TB Alliance (Pretomanid & Sutezolid), and Gates MRI (Sutezolid). These 4 members and the Bill & Melinda Gates Foundation have signed a joint development agreement (JDA) to investigate these novel regimens in a Phase 2 clinical trial that will be conducted by the Gates MRI. The PAN-TB consortium’s goal is to identify a regimen that is suitable for phase 3 development.

Last year, the WGND produced an episode of it's podcast, The Dose, on the topic of the PAN-TB Collaboration. Listen to this episode by clicking here or on Vimeo

To read more about this announcement please visit below:


More News
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...